Ali McBride, PharmD, MS, BCPS, BCOP

Residency Program Director
Department(s): 
Dr. Ali McBride is the Clinical Coordinator of Hematology/Oncology at The University of Arizona Cancer Center and a Clinical Assistant Professor at The University of Arizona College of Pharmacy.  He received his Doctor of Pharmacy degree at The University of Arizona College of Pharmacy, Tucson, AZ and his Bachelor of Science in Neurobiology and Physiology and Masters of Science in Biology from Purdue University.  Ali completed an ASHP-accredited pharmacy practice (PGY1) at Carl T. Hayden VAMC Phoenix, AZ and oncology (PGY2) residency at H. Lee Moffitt Cancer Center Tampa, Fl. Ali is Board-certified in Oncology Pharmacy. Prior to entering the profession of pharmacy, Ali was a research scientist at Memorial Sloan Kettering Cancer Center and Mayo Clinic.  
 
As part of his professional service, Ali has been an active member of ASHP, ACCC and HOPA. Ali’s involvement with ASHP has included serving on the Council on Therapeutics. In addition, he has served on the New Practitioner Advisory Group and as the Vice-Chair and Chair of the Emerging Sciences SAG. Ali has been involved in several HOPA committees including the Legislative Affairs Committee for which he served as the chair.  He currently serves as a working group member for HOPA on its biosimilar committee.  Ali also serves as the advisory board member for ACCC OPEN and holds the office of ACCC Secretary.  Dr. McBride has been working on oncology drug shortages and has testified on behalf of HOPA at FDA Drug Shortage Workshop, presented on behalf of ACCC at the Washington DC Congressional Session and was an invited member of the ASHP Drug Shortage Stakeholders Meeting.  Dr. McBride is also actively involved with Biosimilar regulation and the pharmacoeconomic impact of biosimilars into the US Marketplace.  In addition, he currently serves on the National Quality Forum Cancer Standing Committee.   He has published numerous articles focussing on drug shortages, oral chemotherapy adherence, stem cell transplant and biosimilar implementation into the US health care market.  
Originally posted: September 28, 2017
Last updated: October 31, 2017
Want to update? Contact Webmaster
Share This